LQDA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

82.000

Open

78.870

VWAP

80.58

Vol

1.22M

Mkt Cap

7.22B

Low

78.520

Amount

98.25M

EV/EBITDA(TTM)

148.46

Total Shares

88.93M

7.00B

EV/OCF(TTM)

145.87

P/S(TTM)

24.76

Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler.

Events Timeline

(ET)

2026-06-04

12:10:00

Liquidia Shares Rise 17.6% to $65.50

2026-05-11 (ET)

2026-05-11

16:30:00

Major Averages Close Slightly Higher as Investors Focus on Economic Data

News

7.5

07-06NASDAQ.COM

Analysis of Biotech Companies' Stock Performance

8.5

07-03NASDAQ.COM

United Therapeutics Acquires Thymmune Therapeutics to Enhance Regenerative Medicine Pipeline

8.0

06-26NASDAQ.COM

Teladoc and Liquidia Options Trading Activity Surges

9.5

06-23NASDAQ.COM

Liquidia Corporation Stock Soars with Optimistic Outlook

6.5

06-23NASDAQ.COM

Liquidia Corp. and Goodyear Stock Analysis

8.5

06-19NASDAQ.COM

uniQure Achieves Major Regulatory Milestone for Gene Therapy

8 Analyst Rating

Wall Street analysts forecast LQDA stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

31.00

Averages

47.50

High

67.00

Current: 0.000

Low

31.00

Averages

47.50

High

67.00

BofA

Buy

Neutral

downgrade

$64 -> $79

AI Analysis

2026-06-29

Reason

BofA

Price Target

$64 -> $79

AI Analysis

2026-06-29

downgrade

Buy

Neutral

Reason

BofA downgraded Liquidia to Neutral from Buy with a price target of $79, up from $64. Yutrepia's launch has exceeded the firm's expectations, says the analyst, who raised the peak sales estimate to $2.2B from $1.7B. However, with shares up sharply year-to-date and the PH-ILD related patent litigation unresolved, the firm believes investors need greater clarity on the IP outcome before underwriting additional upside.

BTIG

NULL

Buy

upgrade

$59 -> $109

2026-06-22

Reason

BTIG

Price Target

$59 -> $109

2026-06-22

upgrade

NULL

Buy

Reason

BTIG raised the firm's price target on Liquidia to $109 from $59 and keeps a Buy rating on the shares. The firm is updating its model while noting that the company is likely transitioning to a strong earnings growth story, the analyst tells investors in a research note. BTIG adds that its new methodology reflects the strong operating leverage expected through 2027 and properly accounts for the outcome dispersion related to the '327 bench trial that could have decisions delivered in the near term.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LQDA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Liquidia Corp (LQDA.O) is 38.02, compared to its 5-year average forward P/E of -7.05. For a more detailed relative valuation and DCF analysis to assess Liquidia Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.05

Current PE

38.02

Overvalued PE

16.62

Undervalued PE

-30.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.11

Current EV/EBITDA

12.70

Overvalued EV/EBITDA

8.40

Undervalued EV/EBITDA

-18.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

22.45

Current PS

5.93

Overvalued PS

37.91

Undervalued PS

6.99

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

poet , almu, dell, Ionq, nvts, plug

Intellectia · 253 candidates

Region: USQuarter Revenue Yoy Growth: >= 0.0%Pe Growth Ratio Ttm: <= 3.00Moving Average Relationship: PriceAboveMA200Is Optionable: TrueOption Sentiments: BullishMacd: bullish

Ticker

Name

Market Cap$

LQDA

Liquidia Corp

6.33B

UNIT

Uniti Group Inc (Delaware)

3.10B

CARE

Carter Bankshares Inc

663.88M

NAT

Nordic American Tankers Ltd

1.18B

LPG

Dorian LPG Ltd

1.93B

GROW

US Global Investors Inc

36.72M

resistant to inflation stocks

Intellectia · 41 candidates

Sector: Consumer Cyclicals, Consumer Non-Cyclicals, Healthcare, Healthcare Services & Equipment, Industrials, Industrial & Commercial Services, Industrial Goods, UtilitiesIndustry: Electronic Equipment & Parts, Electric Utilities & IPPs, Food & Drug Retailing, Food & Tobacco, Healthcare Equipment & Supplies, Healthcare Providers & Services, Multiline Utilities, Pharmaceuticals, Professional & Commercial Services, Professional & Business Education, Water & Related UtilitiesRegion: USGross Margin: >= 40.00Beta: LowRiskCurrent Ratio: >= 1.50Operating Margin: >= 10.00Free Cash Flow Ttm: >= 0

Ticker

Name

Market Cap$

HALO

Halozyme Therapeutics Inc

8.14B

ZVRA

Zevra Therapeutics Inc

647.31M

ALNY

Alnylam Pharmaceuticals Inc

39.47B

INVA

Innoviva Inc

1.63B

GILD

Gilead Sciences, Inc

165.99B

CTAS

Cintas Corp

67.97B

what stocks still have growth

Intellectia · 74 candidates

Region: USQuarter Revenue Yoy Growth: >= 20.0%Market Cap Category: mid, large, megaQuarter Eps Yoy Growth: >= 20.0%Revenue 5yr Cagr: >= 15Moving Average Relationship: PriceAboveMA200

Ticker

Name

Market Cap$

LQDA

Liquidia Corp

5.33B

BEAM

Beam Therapeutics Inc

2.71B

SII

Sprott Inc

3.21B

CRDO

Credo Technology Group Holding Ltd

31.17B

AMPX

Amprius Technologies Inc

2.19B

ASND

Ascendis Pharma A/S

14.70B

IPOs to buy

Intellectia · 27 candidates

Market Cap: >= 2.50BRegion: USAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Annual Revenue Yoy Growth: >= 25.0%

Ticker

Name

Market Cap$

LQDA

Liquidia Corp

3.13B

MDGL

Madrigal Pharmaceuticals Inc

10.27B

AMPX

Amprius Technologies Inc

2.56B

BBIO

BridgeBio Pharma Inc

13.49B

WULF

Terawulf Inc

6.87B

VNOM

Viper Energy Inc

16.93B

channel up daily stocks

Intellectia · 103 candidates

Market Cap: >= 1000.00MRegion: USPrice: $3.00 - $300.00Volume: >= 1,000,000Price Change Pct: $3.00 - $100.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

STGW

Stagwell Inc

1.55B

UAMY

United States Antimony Corp

1.57B

NIO

NIO Inc

14.15B

AXTI

AXT Inc

2.45B

VNET

VNET Group Inc

3.02B

BBIO

BridgeBio Pharma Inc

14.41B

List stocks with high sales growth rates.

Intellectia · 665 candidates

Quarter Revenue Yoy Growth: >= 10.0%Revenue 5yr Cagr: >= 10

Ticker

Name

Market Cap$

VMAR

Vision Marine Technologies Inc

4.48M

BBIO

BridgeBio Pharma Inc

15.06B

EOSE

Eos Energy Enterprises Inc

5.68B

BNKK

Bonk Inc

25.65M

SMR

Nuscale Power Corp

5.98B

DOMH

Dominari Holdings Inc

65.65M

Whales Holding LQDA

Caxton Associates (USA) LLC

Farallon Capital Management, L.L.C.

Boothbay Fund Management, LLC

The Caprock Group, LLC

Eversept Partners, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Liquidia Corp (LQDA) stock price today?

The current price of LQDA is 81.23 USD — it has increased 2.55

What is Liquidia Corp (LQDA)'s business?

What is the price predicton of LQDA Stock?

Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is47.50 USD with a low forecast of 31.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.